RSS-Feed abonnieren
DOI: 10.1055/s-2008-1038385
© Georg Thieme Verlag KG Stuttgart · New York
CarboMedics Mitroflow Pericardial Aortic Bioprosthesis - Performance in Patients Aged 60 Years and Older after 15 Years
Publikationsverlauf
received Sept. 11, 2007
Publikationsdatum:
15. Mai 2008 (online)
![](https://www.thieme-connect.de/media/thoracic/200804/lookinside/thumbnails/10.1055-s-2008-1038385-1.jpg)
Abstract
Background: The purpose of this study was to carry out a current assessment of the Mitroflow pericardial bioprosthesis (model 11) according to the durability of the prosthesis after 15 years in patients aged 60 years or older. Methods: This bioprosthesis was implanted in 161 patients (mean age 69.5 ± 6.3 years; range 60 - 94 years) undergoing aortic valve replacement (AVR) between 1982 and 1992. There were 84 patients aged 60 - 69 years (mean 64.5 ± 3.1years) and 77 patients aged 70 years or older (mean 74.8 ± 4.3 years). Of the total population, concomitant procedures were performed in 63 patients (39.1 %); of these, coronary artery bypass grafting was performed in 39 (24.2 %). Results: Early mortality was 4.8 % (4 patients) in the 60 - 69 year age group and 10.4 % (8) in patients aged 70 years or older (p = 0.290). Late mortality was 4.5 %/patient-year (35) for those aged 60 - 69 years and 8.1 %/patient-year (49) for those aged 70 years or older (p = 0.007). Patient survival at 15 years of patients aged 60 - 69 years was 47.6 ± 6.3 % and of patients aged 70 years or older was 20.9 ± 5.4 % (p = 0.003) ([Fig. 1]). Freedom from valve-related mortality for patients in the 60 - 69 year age group was 92.1 ± 3.5 % at 15 years (0.6 %/patient-year [5]), and in the patient group aged 70 years or older it was 84.4 ± 5.3 % (1.3 %/patient-year [8]; p = 0.194). Freedom from reoperation for patients in the 60 - 69 year age group was 73.9 ± 5.0 % (2.6 %/patient-year [20]), and for patients aged 70 years or older it was 91.4 ± 3.4 % (1.0 %/patient-year [6]; p = 0.029). The structural valve deterioration (SVD) rate for patients in the 60 - 69 year age group was 2.4 %/patient-year (19), and for patients aged 70 years or older it was 1.0 %/patient-year (6) (p = 0.041). Actuarial freedom from structural valve deterioration at 15 years for patients aged 60 - 69 years was 62.0 ± 7.3 %, and 80.8 ± 7.9 % for patients aged 70 years and older (p = 0.049) (actual freedom 73.9 ± 5.2 % and 91.4 ± 3.4 %, respectively). Conclusions: The Mitroflow pericardial bioprosthesis can still be recommended for aortic valve replacement in patients 70 years and older.
Key words
heart valve surgery - aortic disease - cardiovascular surgery - heart disease
References
- 1 Ionescu M I, Tandon A P, Mary D AS, Abid A. Heart valve replacement with Ionescu-Shiley pericardial xenograft. J Thorac Cardiovasc Surg. 1977; 73 31-42
- 2 Jamieson W RE, Janusz M T, MacNab J, Henderson C. Hemodynamic comparison of second- and third generation stented bioprostheses in aortic valve replacement. Ann Thorac Surg. 2001; 71 (Suppl 5) S282-S284
- 3 Franzen S, Nylander E, Olin C. Aortic valve replacement with pericardial valves in patients with small aortic roots. Clinical results in a consecutive series of patients receiving 19 and 21 mm prostheses. Scand Cardiovasc J. 2001; 35 114-118
- 4 Pomar J L, Jamieson W RE, Pelletier L C, Gerein A N, Castella M, Brownlee R T. Mitroflow pericardial bioprosthesis: clinical performance to ten years. Ann Thorac Surg. 1995; 60 S305-S310
- 5 Mazzucotelli J P, Bertrand P C, Loisance D Y. The Mitroflow pericardial valve: clinical performance to ten years. J Heart Valve Dis. 1995; 4 407-413
- 6 Minami K, Schereika S, Kortke H, Gleichmann U, Korfer R. Long term follow up of Mitroflow pericardial valve bioprosthesis in the small aortic annulus. J Cardiovasc Surg. 1993; 34 189-193
- 7 Pomar J L, Jamieson W RE, Pelletier L, Castella M, Germann E, Brownlee R T. Mitroflow pericardial bioprosthesis experience in aortic valve replacement ≥ 60 years of age. Ann Thorac Surg. 1998; 66 S53-S56
- 8 Edmunds L H, Richard E, Lawrence H, Gary L, Miller D C, Richard D. Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ann Thorac Surg. 1996; 62 932-935
- 9 Yankah C, Schubel J, Buz S, Siniawski H, Hetzer R. Seventeen year clinical results of 1037 Mitroflow pericardial heart valve prostheses in the aortic position. J Heart Valve Dis. 2005; 14 172-180
- 10 Thulin L I, Thielen U J, Kymie K AF. Mitroflow pericardial bioprosthesis in the aortic position. Low incidence of structural valve deterioration in elderly patients during a 11-year follow-up. Scand Cardiovasc J. 2000; 34 192-196
- 11 Minami K, Zittermann A, Schulte-Eistrup S, Koertke H, Korfer R. Mitroflow synergy prostheses for aortic valve replacement: 19 years experience with 1516 patients. Ann Thorac Surg. 2005; 80 1699-1705
- 12 Minami K, Boethig D, Mirow N, Kleikamp G, Koertke H, Godehardt E, Koerfer R. Mitroflow pericardial valve prosthesis in the aortic position: an analysis of long-term outcome and prognostic factors. J Heart Valve Dis. 2000; 9 112-122
- 13 Jamieson W RE, Burr L H, Miyagishima R T, Germann E. et al . Carpentier-Edwards supra-annular porcine bioprosthesis: clinical performance over 20 years. J Thorac Cardiovasc Surg. 2005; 130 994-1000
- 14 Gonzalez J, Garcia B, Garcia A, Vega Fernandez M, Amaro Cendon A, Varela Roman A, Gil de la Pena M. The influence of the design on the medium to long-term hemodynamic behavior of 19 mm pericardial aortic valve prostheses. J Heart Valve Dis. 1996; 5 (Suppl 3) S317-S323
- 15 Gonzalez J, Garcia B, Garcia A, Vega Fernandez M, Amaro Cendon A, Castelo Fuentes V, Garcia-Bengoechea J B, Gil de la Pena M. Hemodynamics of various designs of 19 mm pericardial aortic valve bioprosthesis. Eur J Cardiothorac Surg. 1996; 10 201-206
- 16 Jamieson W RE, Germann E, Aupart M R, Neville P H, Marchand M A, Fradet G J. 15-year comparison of supra-annular porcine and perimount aortic bioprostheses. Asian Cardiovasc Thorac Annals. 2006; 14 200-205
- 17 Yankah C, Minami K, Zittermann A, Stein J, Koertke H, Siniawski H, Koerfer R, Hetzer R. Two institutional clinical results of Mitroflow pericardial aortic bioprostheses in 3029 patients: Twenty-year experience (including personal communication). Society for Heart Valve Disease. 2007 presentation
Prof., MD W. R. Eric Jamieson
Division of Cardiovascular Surgery
University of British Columbia
St. Paul's Hospital
486 Burrard Bldg.
1081 Burrard Street
V6Z 1Y6 Vancouver
Canada
Telefon: + 1 60 48 06 83 83
Fax: + 1 60 48 06 83 84
eMail: eric.jamieson@ubc.ca